{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4,760,000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Number of CD34-positive cells collected per kg recipient body weight","groups":[{"description":"Donors receive filgrastim subcutaneously (SC) and plerixafor SC on day -14 and undergo leukapheresis to collect peripheral blood stem cells (PBSC) on day -13. These cells are frozen to preserve them. Treatment modifications may apply according to sufficient collection of PBSC. Patients receive standard high-dose conditioning and undergo allogeneic PBSC transplantation on day 0 using the previously frozen cells.\n\nAfter completion of study treatment, donors are followed up 1 day after the last stem cell donation.\n\nplerixafor: Given SC\n\nfilgrastim: Given SC\n\nperipheral blood stem cell transplantation: Infusion of peripheral blood stem cells\n\nallogeneic hematopoietic stem cell transplantation: Infusion of hematopoietic stem cells","id":"OG000","title":"Filgrastim and Plerixafor for PBSC Mobilization"}],"paramType":"NUMBER","populationDescription":"Trial terminated; only one patient enrolled","reportingStatus":"POSTED","timeFrame":"At the end of apheresis for cell collection","title":"CD34-positive Cells Collected","type":"SECONDARY","unitOfMeasure":"CD34-positive cells collected/kg"}